AlphaCentric Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

AlphaCentric Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-75,000	Closed	-$934K	–	254
2024 Q3	$934K	Hold	75,000	–	–	0.69%	51
2024 Q2	$976K	Hold	75,000	–	–	0.72%	46
2024 Q1	$1.7M	Hold	75,000	–	–	1.02%	31
2023 Q4	$973K	Hold	75,000	–	–	0.65%	56
2023 Q3	$1.51M	Buy	75,000 +21,000	+39%	+$471K	0.85%	38
2023 Q2	$1.45M	Buy	54,000 +38,000	+238%	+$1.64M	0.8%	44
2023 Q1	$934K	Buy	+16,000	New	+$790K	0.64%	57
2021 Q4	$900K	Buy	9,333 +266	+3%	+$26.5K	0.26%	37
2021 Q3	$792K	Buy	9,067 +3,634	+67%	+$377K	0.2%	43
2021 Q2	$841K	Buy	5,433 +1,966	+57%	+$285K	0.23%	33
2021 Q1	$547K	Buy	3,467 +2,334	+206%	+$492K	0.18%	41
2020 Q4	$263K	Buy	+1,133	New	+$263K	0.11%	48

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AlphaCentric Advisors's KPTI Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 75,000 shares — an estimated $934K sold.

AlphaCentric Advisors first reported a position in KPTI in Q4 2020 and held it in 12 quarters. The position peaked at $1.7M in Q1 2024. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

AlphaCentric Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 75,000 Karyopharm Therapeutics shares in Q4 2024, an estimated $934K.
AlphaCentric Advisors first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 12 quarters.
AlphaCentric Advisors's Karyopharm Therapeutics position peaked at $1.7M in Q1 2024.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.